IDH1 R132H mutation regulates glioma chemosensitivity through Nrf2 pathway

Kaishu Li1,2,3, Leping Ouyang1, Mingliang He1,2

  • 1Department of Neurosurgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, PR China.

Oncotarget
|April 22, 2017
PubMed
Abstract

Insights

The isocitrate dehydrogenase 1 (IDH1) R132H mutation increases glioma sensitivity to temozolomide by decreasing nuclear factor-erythroid 2-related factor 2 (Nrf2) expression, revealing a key mechanism for drug resistance.

Area of Science:

  • Neuro-oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Glioma patients with IDH1 R132H mutations often show temozolomide sensitivity.
  • The precise mechanism underlying IDH1 mutations' impact on glioma chemosensitivity is not fully understood.

Purpose of the Study:

  • To investigate the role of nuclear factor-erythroid 2-related factor 2 (Nrf2) in IDH1 R132H-mediated drug resistance in glioma.
  • To elucidate the potential molecular mechanisms involved.

Main Methods:

  • Generated stable U87 and U251 cell lines overexpressing wild-type IDH1 (IDH1-WT) and mutant IDH1 (IDH1 R132H).
  • Assessed phenotypic differences using MTT assays, colony formation assays, scratch tests, and flow cytometry.
  • Analyzed the expression of IDH1, Nrf2, NAD(P)H quinine oxidoreductase 1 (NQO1), multidrug resistant protein 1 (MRP1), and p53.

Main Results:

  • IDH1 R132H overexpressing cells demonstrated increased sensitivity to temozolomide compared to IDH1-WT cells.
  • Nrf2 expression and nuclear translocation were significantly decreased in IDH1 R132H cells, particularly after temozolomide treatment.
  • Knocking down Nrf2 reduced temozolomide resistance, and reduced NQO1 expression was observed in IDH1 R132H cells, with p53 involvement noted.

Conclusions:

  • Nrf2 plays a critical role in IDH1 R132H-mediated temozolomide resistance in glioma.
  • This study offers novel insights into glioma chemotherapy strategies involving temozolomide.

Related Concept Videos

NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
10.1K
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
5.6K
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.8K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.3K